ALX ONCOLOGY HOLDINGS INC
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
ALXO$1.29+11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| Year Ended | |||
|---|---|---|---|
| December 31, | |||
| 2023 | 2022 | 2021 | |
| Operating expenses: | |||
| Research and development | $141,795 | $98,400 | 60,170 |
| General and administrative | 28,483 | 29,036 | 23,385 |
| Total operating expenses | 170,278 | 127,436 | 83,555 |
| Loss from operations | (170,278) | (127,436) | (83,555) |
| Interest income | 10,649 | 4,278 | 91 |
| Interest expense | (1,565) | (238) | (13) |
| Other income (expense), net | 389 | (22) | (7) |
| Loss before income taxes | (160,805) | (123,418) | (83,484) |
| Income tax (provision) benefit | — | (64) | 21 |
| Net loss | $(160,805) | $(123,482) | (83,463) |
| Net loss per share, basic and diluted | $(3.74) | $(3.03) | $(2.07) |
| Weighted-average shares of common stock used to compute net loss per share, basic and diluted | 42,987,767 | 40,699,612 | 40,308,050 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.